CIK 0001477449 · Large accelerated filer
Teladoc Health, Inc.
Sign in to watch- Ticker
- TDOC
- Exchange
- NYSE
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043705970
- Phone
- 2036352002
- Business address
- 155 E 44TH STREET, SUITE 1700, NEW YORK, NY, 10017
- Former names
- Teladoc, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $731,651
- in 9 filings, $369K under 10b5-1 plans
Net −$731,651. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Nueno Carlos −$310K President, International sold 50% of stake
- DIVITA CHARLES III −$224K CHIEF EXECUTIVE OFFICER sold 7% of stake
- Rodrigues Fernando M. −$98K President of BetterHelp sold 100% of stake
- Vandervoort Adam C −$48K CHIEF LEGAL OFFICER, SECRETARY sold 6% of stake
- Bliss Kelly −$46K President, U.S. Group Health sold 7% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-01 | Verstraete Stephany Chief Marketing Officer | Option exercise | +7,000 | $22.30 | $156K | 20,276 |
| 2021-02-01 | Verstraete Stephany Chief Marketing Officer | Sale | −7,000 | $265.02 | $1.9M | 13,276 |
| 2021-02-01 | Verstraete Stephany Chief Marketing Officer | Option exercise · Employee Stock Option (right to buy) | −7,000 | 12,600 | ||
| 2021-01-25 | WANG YULUN Head of Research & Development | Sale | −8,261 | $280.00 | $2.3M | 219,507 |
| 2021-01-22 | WANG YULUN Head of Research & Development | Sale | −8,000 | $260.00 | $2.1M | 227,768 |
| 2021-01-20 | WANG YULUN Head of Research & Development | Sale | −8,000 | $240.00 | $1.9M | 235,768 |
| 2021-01-14 | TULLMAN GLEN Director | Option exercise | +164,931 | $5.26 | $868K | 440,724 |
| 2021-01-14 | TULLMAN GLEN Director | Sale | −164,931 | $225.12 | $37.1M | 275,793 |
| 2021-01-14 | TULLMAN GLEN Director | Option exercise · Stock Option (right to buy) | −164,931 | 659,725 | ||
| 2021-01-14 | WANG YULUN Head of Research & Development | Sale | −8,000 | $226.66 | $1.8M | 243,768 |
| 2021-01-14 | Geshuri Arnnon Chief Human Resources Officer | Option exercise | +1,750 | $2.73 | $5K | 102,569 |
| 2021-01-14 | Geshuri Arnnon Chief Human Resources Officer | Sale | −1,750 | $226.66 | $397K | 100,819 |
| 2021-01-14 | Geshuri Arnnon Chief Human Resources Officer | Option exercise · Employee Stock Option (right to buy) | −1,750 | 237,378 | ||
| 2021-01-11 | Trencher Daniel SVP Corporate Strategy | Option exercise | +3,000 | $22.30 | $67K | 11,413 |
| 2021-01-11 | Trencher Daniel SVP Corporate Strategy | Sale | −3,000 | $227.33 | $682K | 8,413 |
| 2021-01-11 | Trencher Daniel SVP Corporate Strategy | Option exercise · Employee Stock Option (right to buy) | −3,000 | 46,414 | ||
| 2021-01-06 | Verstraete Stephany Chief Marketing Officer | Option exercise | +3,000 | $22.30 | $67K | 16,276 |
| 2021-01-06 | Verstraete Stephany Chief Marketing Officer | Sale | −3,000 | $204.00 | $612K | 13,276 |
| 2021-01-06 | Verstraete Stephany Chief Marketing Officer | Option exercise · Employee Stock Option (right to buy) | −3,000 | 19,600 | ||
| 2021-01-05 | GOREVIC JASON N Chief Executive Officer | Sale | −30,000 | $200.15 | $6.0M | 557,188 |
Page 83 of 93 · 1,848 trades